glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde
Company profile
Ticker
GKOS
Exchange
Website
CEO
Thomas Burns
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GLAUKOS CORP
SEC CIK
Corporate docs
Subsidiaries
Glaukos Germany GmbH • Glaukos Australia Pty Ltd • Glaukos Canada Inc. • Glaukos France SAS • Glaukos Ireland Limited • Glaukos Netherlands B.V. • Glaukos Produtos Médicos Ltda. • Glaukos Sweden AB • Glaukos UK Limited • Glaukos Singapore PTE. LTD. ...
GKOS stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
16 Apr 24
DEF 14A
Definitive proxy
16 Apr 24
DEFA14A
Additional proxy soliciting materials
16 Apr 24
S-8
Registration of securities for employees
15 Mar 24
8-K
Investor Presentation February 2024
28 Feb 24
10-K
2023 FY
Annual report
23 Feb 24
8-K
Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
21 Feb 24
8-K
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance
9 Jan 24
8-K
Revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease severity
14 Dec 23
10-Q
2023 Q3
Quarterly report
1 Nov 23
Transcripts
GKOS
Earnings call transcript
2023 Q4
21 Feb 24
GKOS
Earnings call transcript
2023 Q3
1 Nov 23
GKOS
Earnings call transcript
2023 Q2
2 Aug 23
GKOS
Earnings call transcript
2023 Q1
3 May 23
GKOS
Earnings call transcript
2022 Q4
22 Feb 23
GKOS
Earnings call transcript
2022 Q3
5 Nov 22
GKOS
Earnings call transcript
2022 Q2
4 Aug 22
GKOS
Earnings call transcript
2022 Q1
4 May 22
GKOS
Earnings call transcript
2021 Q4
23 Feb 22
GKOS
Earnings call transcript
2021 Q3
7 Nov 21
Latest ownership filings
4
David F Hoffmeister
12 Apr 24
4
Joseph E Gilliam
10 Apr 24
4
Alex R. Thurman
9 Apr 24
4
Joseph E Gilliam
9 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
4
Joseph E Gilliam
5 Apr 24
4
Alex R. Thurman
5 Apr 24
144
Notice of proposed sale of securities
5 Apr 24
144
Notice of proposed sale of securities
5 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 114.79 mm | 114.79 mm | 114.79 mm | 114.79 mm | 114.79 mm | 114.79 mm |
Cash burn (monthly) | (no burn) | (no burn) | 10.14 mm | 10.90 mm | 2.72 mm | 4.27 mm |
Cash used (since last report) | n/a | n/a | 69.29 mm | 74.48 mm | 18.61 mm | 29.18 mm |
Cash remaining | n/a | n/a | 45.50 mm | 40.30 mm | 96.17 mm | 85.60 mm |
Runway (months of cash) | n/a | n/a | 4.5 | 3.7 | 35.3 | 20.1 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 234 |
Opened positions | 31 |
Closed positions | 14 |
Increased positions | 83 |
Reduced positions | 80 |
13F shares | Current |
---|---|
Total value | 3.71 tn |
Total shares | 51.47 mm |
Total puts | 164.10 k |
Total calls | 186.10 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 7.90 mm | $594.46 bn |
Vanguard | 5.24 mm | $394.31 bn |
FMR | 3.48 mm | $262.05 bn |
Brown Capital Management | 2.61 mm | $196.28 bn |
Wellington Management | 2.06 mm | $154.75 bn |
Alger Associates | 2.02 mm | $74.09 mm |
Fred Alger Management | 1.78 mm | $134.00 bn |
STT State Street | 1.77 mm | $132.88 bn |
JHG Janus Henderson | 1.62 mm | $121.54 bn |
IVZ Invesco | 1.45 mm | $109.11 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Apr 24 | Hoffmeister David F | Common Stock | Option exercise | Acquire M | No | No | 7.275 | 10,000 | 72.75 k | 15,767 |
10 Apr 24 | Hoffmeister David F | Stock Option Common Stock | Option exercise | Dispose M | No | No | 7.275 | 10,000 | 72.75 k | 0 |
8 Apr 24 | Gilliam Joseph E | Common Stock | Sell | Dispose S | No | Yes | 102.13 | 86 | 8.78 k | 101,845 |
8 Apr 24 | Gilliam Joseph E | Common Stock | Sell | Dispose S | No | Yes | 101.28 | 8,191 | 829.58 k | 101,931 |
8 Apr 24 | Gilliam Joseph E | Common Stock | Sell | Dispose S | No | Yes | 100.52 | 41,068 | 4.13 mm | 110,122 |
8 Apr 24 | Gilliam Joseph E | Common Stock | Sell | Dispose S | No | Yes | 99.64 | 10,456 | 1.04 mm | 151,190 |
8 Apr 24 | Gilliam Joseph E | Common Stock | Option exercise | Acquire M | No | No | 41.69 | 59,801 | 2.49 mm | 161,646 |
8 Apr 24 | Gilliam Joseph E | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 41.69 | 59,801 | 2.49 mm | 0 |
8 Apr 24 | Alex R. Thurman | Common Stock | Sell | Dispose S | No | Yes | 100.46 | 1,227 | 123.26 k | 52,532 |
8 Apr 24 | Alex R. Thurman | Common Stock | Sell | Dispose S | No | Yes | 101.24 | 145 | 14.68 k | 53,759 |
News
Mizuho Maintains Neutral on Glaukos, Raises Price Target to $100
11 Apr 24
Analyst Ratings For Glaukos
8 Apr 24
Truist Securities Reiterates Buy on Glaukos, Maintains $110 Price Target
8 Apr 24
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
3 Apr 24
Stifel Reiterates Buy on Glaukos, Maintains $110 Price Target
3 Apr 24